Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gamma interferon is critical for resistance to Theiler's virus-induced demyelination.

Journal of virology·1995
Same author

Epidemiology of hepatitis D virus infection: changes in the last 14 years.

The American journal of gastroenterology·1995
Same author

Comparison of Z and multivariate statistical brain electromagnetic maps for the localization of brain lesions.

Electroencephalography and clinical neurophysiology·1995
Same author

Lethality and survival of Klebsiella oxytoca evoked by conjugative IncN group plasmids.

Journal of bacteriology·1995
Same author

Predicting malignancy grade with PET in non-Hodgkin's lymphoma.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·1995
Same author

Idiopathic dialysis ascites in the nineties: resolution after renal transplantation.

American journal of kidney diseases : the official journal of the National Kidney Foundation·1995

Related Experiment Video

Updated: Jul 8, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.

S J Pittock1, M Rodriguez

  • 1Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. pittock.sean@mayo.edu

Current Topics in Microbiology and Immunology
|January 29, 2008
PubMed
Summary

Multiple Sclerosis (MS) patients with low disability (EDSS ≤ 2) show minimal risk of future disability progression. This suggests an individualized approach to disease-modifying treatments for MS is warranted.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Related Experiment Videos

Last Updated: Jul 8, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Area of Science:

  • Neurology
  • Clinical Medicine
  • Epidemiology

Background:

  • Multiple Sclerosis (MS) is a chronic neurological disease with variable progression.
  • The concept of benign multiple sclerosis remains debated.
  • Understanding the natural history of MS is crucial for treatment decisions.

Purpose of the Study:

  • To review the natural history of Multiple Sclerosis, focusing on benign MS.
  • To evaluate the efficacy and safety of disease-modifying agents for MS.
  • To propose an individualized treatment strategy for MS patients.

Main Methods:

  • Analysis of the Olmsted County population prevalence cohort study.
  • Review of evidence-based medicine regarding MS treatments.
  • Assessment of disease-modifying agents' indications, efficacy, mechanism, and side effects.

Main Results:

  • MS patients with low Expanded Disability Status Scale (EDSS) scores (≤ 2) have a low risk of disability progression over 10-20 years.
  • Disease-modifying agents show varying efficacy and side effect profiles.
  • Evidence supports both benefits and risks of treating all MS patients.

Conclusions:

  • An individualized approach to disease-modifying therapy in MS is recommended.
  • Treatment decisions should consider the natural history and patient-specific factors.
  • Further research into optimal MS treatment strategies is ongoing.